title: Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan.
abstract: The incidence of adult T-cell leukemia/lymphoma (ATL) and its impact on that of total non-Hodgkin lymphoma (NHL) were evaluated in Nagasaki, an area in southwestern Japan where human T-cell lymphotropic virus type I (HTLV-I) is endemic. The first study area comprised 4 towns located on the K Islands, which had a population of 26,870 in 1990. The overall HTLV-I seroprevalence estimated from the serologic survey of 18,485 subjects was 16.2%. By using the data from the Nagasaki Prefectural Cancer Registry (NPCR) and reviewing clinical and laboratory information, we identified 40 cases of ATL and 35 cases of other NHL diagnosed between 1985 and 1995. The crude annual incidence of ATL among 100,000 HTLV-I carriers aged 30 or older was estimated at 137.7 for men and 57.4 for women, with a significant sex difference after adjustment for age (rate ratio = 2.50, 95% confidence interval 1.32-4.73). The cumulative risk from 30 to 79 years of age was estimated at approximately 6.6% for men and 2.1% for women. Among the entire population, ATL accounted for 51 to 59% of the total NHL incidence, showing the strong impact of HTLV-I infection. The second study area comprised the whole of Nagasaki Prefecture (total population in 1990 = 1.56 million). Between 1985 and 1995, 989 cases of ATL and 1,745 cases of other NHL were registered in the NPCR. The world age-standardized annual incidence rate of ATL per 100,000 persons aged 30 or older was estimated at 10.5 for men and 6.0 for women, which accounted for approximately 37 to 41% of the total NHL incidence.
authors.affiliation: Department of Preventive Medicine and Health Promotion, Nagasaki University School of Medicine, Japan. k-iwata@net.nagasaki-u.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Arisawa
authors.forename: M
authors.initials: M
authors.lastname: Soda
authors.forename: S
authors.initials: S
authors.lastname: Endo
authors.forename: K
authors.initials: K
authors.lastname: Kurokawa
authors.forename: S
authors.initials: S
authors.lastname: Katamine
authors.forename: I
authors.initials: I
authors.lastname: Shimokawa
authors.forename: T
authors.initials: T
authors.lastname: Koba
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Doi
authors.forename: S
authors.initials: S
authors.lastname: Shirahama
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D005260:Female; D015368:Human T-lymphotropic virus 1 / Q000276:immunology; D006801:Humans; D015994:Incidence; D007223:Infant; D007564:Japan / Q000453:epidemiology; D015458:Leukemia, T-Cell / Q000453:epidemiology* / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000821:virology; D016399:Lymphoma, T-Cell / Q000453:epidemiology* / Q000821:virology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012306:Risk; D017678:Sex Distribution
chemical_list: D000914:Antibodies, Viral